BiotechTube
AVM Biotechnology

AVM Biotechnology

Seattle, United States· Est.
avmbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.5M

Overview

AVM Biotechnology is a private, clinical-stage company advancing its lead asset, AVM0703, a novel immunomodulatory therapy. The drug is currently in a pivotal Phase 2 trial for relapsed/refractory non-Hodgkin's lymphoma and leukemia, with a compassionate use program also active. Founded and led by Dr. Theresa Deisher, the company focuses on leveraging a unique mechanism of immune cell mobilization to address cancers and autoimmune conditions with high unmet need.

OncologyAutoimmune DiseasesInfectious Diseases

Technology Platform

Proprietary high-dose dexamethasone formulation designed to mobilize unique gamma delta T cells, invariant NKT-like cells, and bispecific T lymphocytes from the body's endogenous reserves.

Funding History

11
Total raised:$15.5M
Grant$1000K
Grant$964K
Grant$399K
Grant$1000K

Opportunities

AVM0703 addresses large, high-need markets in relapsed/refractory blood cancers and ARDS, where effective treatments are limited.
Its novel mechanism as a pharmacologic immune mobilizer could offer a simpler, more accessible alternative to complex engineered cell therapies.
Positive Phase 2 data could enable accelerated approval pathways and attract strategic partnerships.

Risk Factors

The primary risk is clinical failure of AVM0703 in its pivotal Phase 2 trial, particularly regarding efficacy or safety of the high-dose steroid regimen.
The company faces intense competition in oncology and depends on continued grant funding and private investment as a pre-revenue entity.
The novel scientific mechanism, while promising, requires robust clinical validation.

Competitive Landscape

In hematologic cancers, AVM0703 competes with a crowded field of targeted therapies, bispecific antibodies (e.g., blinatumomab, mosunetuzumab), and approved CAR-T cell therapies. Its potential differentiation lies in its simplicity (single-dose, pharmacologic) and potential as a bridge to transplant. In ARDS, it would compete against supportive care and a few late-stage investigational drugs, representing a less crowded but high-stakes arena.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →